Komori
Occurring Fact4596Kubota Pharmaceutical Holdings Co.,Ltd.Pharmaceuticals

(Update on Previously Disclosed Matter) Notice of commencement of manufacturing of emixustat hydrochloride drug product, a Stargardt disease treatment candidate, toward compassionate access authorization in France

The wholly owned subsidiary Kubota Vision has begun manufacturing oral tablets, the final drug product for the Stargardt disease treatment candidate Retakubo to be provided to designated patients in France. This marks the transition from active pharmaceutical ingredient manufacturing to final drug product manufacturing.

Worth reading
31Immaterial
Scored from 4 of 5 sections
Direction
Improvement
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Conditional
How definitive the wording is.

Commencement of manufacturing of the final drug product (oral tablets) for the Stargardt disease treatment candidate emixustat hydrochloride (Retakubo) toward compassionate access authorization in France

Subject Entity

Kubota Vision Inc. (a wholly owned subsidiary of Kubota Pharmaceutical Holdings Co.,Ltd.)

Target Locations / Products

The final drug product (oral tablets) for the Stargardt disease treatment candidate emixustat hydrochloride (Retakubo) for France

This disclosure11/19/2026

Related procedures

Type

Patient-specific application and approval procedures under compassionate access (AAC)

Court or authority

French National Agency for Medicines and Health Products Safety (ANSM)

Impact on Earnings Forecast

We expect the impact on our financial results to be minor.

Outlook

Kubota Vision, in collaboration with KÔL, will continue advancing preparations to make Retakubo available in France, including activities to support the relevant regulatory procedures.

Planned follow-up disclosure

The Company will promptly disclose any matters that arise requiring disclosure.

Event that occurred
ItemDetails
Event nameCommencement of manufacturing of the final drug product (oral tablets) for the Stargardt disease treatment candidate emixustat hydrochloride (Retakubo) toward compassionate access authorization in France
Subject EntityKubota Vision Inc. (a wholly owned subsidiary of Kubota Pharmaceutical Holdings Co.,Ltd.)
Target Locations / ProductsThe final drug product (oral tablets) for the Stargardt disease treatment candidate emixustat hydrochloride (Retakubo) for France
Impact on Earnings ForecastWe expect the impact on our financial results to be minor.
Type of litigation or proceedingPatient-specific application and approval procedures under compassionate access (AAC)
Court or authorityFrench National Agency for Medicines and Health Products Safety (ANSM)
OutlookKubota Vision, in collaboration with KÔL, will continue advancing preparations to make Retakubo available in France, including activities to support the relevant regulatory procedures.
Planned follow-up disclosureThe Company will promptly disclose any matters that arise requiring disclosure.
Items this document does not state (17)
Date of occurrenceDate recognized / date notice receivedCauseAmount of Impact on Business PerformanceAccounting period in which recognizedPlaintiffDefendantDate of filing / date of actionClaim amount / surcharge amountAmount of receivables at risk of non-collection or delayed collectionSuspended operationsScheduled resumption dateInvestigation structureMeasures to prevent recurrenceDirectors' and officers' liabilityVoting rights ownership percentage before the changeVoting rights ownership percentage after the change

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The final drug product is being manufactured in preparation for providing Retakubo to patients under France's compassionate access program. Approval from the French National Agency for Medicines and Health Products Safety (ANSM) is required for each patient-specific application.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
(Update on Previously Disclosed Matter) Notice of commencement of manufacturing of emixustat hydrochloride drug product, a Stargardt disease treatment candidate, toward compassionate access authorization in France | Kubota Pharmaceutical Holdings Co.,Ltd. (4596) timely disclosure | Komori